Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE

185.800
+0.8000.43%
Volume:5.02M
Turnover:940.29M
Market Cap:286.32B
PE:-50.76
High:190.700
Open:185.000
Low:184.400
Close:185.000
52wk High:213.000
52wk Low:103.100
Shares:1.54B
HK Float Shares:1.43B
Volume Ratio:1.66
T/O Rate:0.35%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-3.661
ROE:-4.98%
ROA:-1.06%
PB:9.77
PE(LYR):-50.76
PS:8.08

Loading ...

Company Profile

Company Name:
BEIGENE
Exchange:
SEHK
Establishment Date:
2010
Employees:
11000
Office Location:
Aeschengraben 27,21st Floor,Basel,Basel-Stadt,Switzerland
Zip Code:
4051
Fax:
- -
Introduction:
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

Directors

Name
Position
John V. Oyler
Co-Founder, Chairman and Chief Executive Officer
Ranjeev Krishana
Lead Director
Alessandro Riva
Director
Anthony C. Hooper
Director
Corazon D. Sanders
Director
Margaret Dugan
Director
Michael Goller
Director
Olivier Brandicourt
Director
Qingqing Yi
Director
Shalini Sharp
Director
Xiaodong Wang
Director

Shareholders

Name
Position
John V. Oyler
Co-Founder, Chairman and Chief Executive Officer
Xiaobin Wu
President, Chief Operating Officer and General Manager, China
Aaron Rosenberg
Chief Financial Officer
Chan Lee
Senior Vice President, General Counsel
Lai Wang
Global Head of R&D
Titus Ball
Chief Accounting Officer